Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Hooning

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Netherlands Journal of Surgery|August 1, 1991
Changing indications for breast conserving therapy: proportion of patients with operable breast cancer suitable for breast conservationM J Hooning, J A van Dongen, G Went
Journal of the National Cancer Institute|August 13, 2015
ResponseB A M Heemskerk-Gerritsen, M J Hooning, M A Rookus, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 1, 1992
Breast cancer: a study into the value of a historical group as comparative material for new methods of treatmentM J Hooning, J A van Dongen, A A Hart, et al.
Breast (Edinburgh, Scotland)|March 20, 2023
The effect of attendance in the Dutch breast cancer screening program on breast tumor characteristics among migrant womenR R E Dassen, S Pelders, L de Munck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2011
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patientsP M L H Vencken, M Kriege, D Hoogwerf, et al.
British Journal of Cancer|June 12, 2014
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapyM Kriege, A Hollestelle, A Jager, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2013
Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysisB A M Heemskerk-Gerritsen, M B E Menke-Pluijmers, A Jager, et al.
Familial Cancer|February 22, 2015
Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyM R Wevers, M K Schmidt, E G Engelhardt, et al.
Journal of the National Cancer Institute|March 20, 2015
Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reductionB A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, et al.
British Journal of Cancer|February 20, 2014
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association ConsortiumD Agarwal, S Pineda, K Michailidou, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Netherlands Journal of Surgery|August 1, 1991
Changing indications for breast conserving therapy: proportion of patients with operable breast cancer suitable for breast conservationM J Hooning, J A van Dongen, G Went
Journal of the National Cancer Institute|August 13, 2015
ResponseB A M Heemskerk-Gerritsen, M J Hooning, M A Rookus, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 1, 1992
Breast cancer: a study into the value of a historical group as comparative material for new methods of treatmentM J Hooning, J A van Dongen, A A Hart, et al.
Breast (Edinburgh, Scotland)|March 20, 2023
The effect of attendance in the Dutch breast cancer screening program on breast tumor characteristics among migrant womenR R E Dassen, S Pelders, L de Munck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2011
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patientsP M L H Vencken, M Kriege, D Hoogwerf, et al.
British Journal of Cancer|June 12, 2014
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapyM Kriege, A Hollestelle, A Jager, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2013
Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysisB A M Heemskerk-Gerritsen, M B E Menke-Pluijmers, A Jager, et al.
Familial Cancer|February 22, 2015
Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyM R Wevers, M K Schmidt, E G Engelhardt, et al.
Journal of the National Cancer Institute|March 20, 2015
Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reductionB A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, et al.
British Journal of Cancer|February 20, 2014
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association ConsortiumD Agarwal, S Pineda, K Michailidou, et al.
Pageof 1